India Pharma Outlook Team | Wednesday, 23 September 2026
Novo Nordisk drives a bold triple play across pills, prevention, and new markets as it reshapes its future in the booming GLP-1 segment.
The Danish drugmaker pushes oral weight-loss therapies harder, renews a global childhood obesity prevention drive with UNICEF, and eyes fresh commercial territory such as hair loss.
These moves arrive roughly a year into CEO Mike Doustdar’s tenure and signal a broader strategic signature: market segmentation, portfolio breadth, and category expansion beyond the injectable-only bet that defined earlier years.
Oral Wegovy already claims more than 80 percent of new oral prescriptions in the United States while oral therapies make up about a third of U.S. obesity prescriptions.
Doustdar now prepares for a market that could split 50-50 between pills and injectables by 2030. At the same time the company invests in prevention and scouts adjacent consumer-facing categories. The combination creates clear commercial momentum and a public health counterpoint that readers can weigh for themselves.
Doustdar tells Reuters that weight-loss pills could capture as much as half of the global obesity drug market by 2030. Novo prepares for that scenario while rivals stay heavily focused on injectables. Competitors’ pipelines currently show eight injectables for every two pills under development, a dynamic Doustdar says could favor Novo over the longer term.
“What happens if by 2030 the market is 50/50 (pills-to-injectables)?” he asks. “We are preparing ourselves for all scenarios, including that one.”
Also Read: 10 GLP-1 Drugs Revolutionizing Diabetes & Obesity Treatment
Key numbers underscore the shift already under way:
Wall Street currently expects oral treatments to account for only 14 percent to 40 percent of an obesity market projected to reach USD 100 billion to USD 150 billion by 2030. Doustdar’s 50-50 vision therefore exceeds those forecasts and marks a clear rise in ambition for the oral franchise.
On the same day Novo announces the oral market outlook, the company expands its partnership with UNICEF to prevent childhood overweight and obesity. The expansion follows UNICEF’s 2025 Child Nutrition Report, which found that childhood obesity has overtaken underweight for the first time on record.
Novo commits an additional USD 18 million from 2026 through 2030 to support prevention initiatives in Mexico, Colombia, Indonesia, the Philippines, India, Egypt, and Kenya. The four-year program runs from 2027 to 2030 and aims to reach more than 80 million children.
Interventions include nutrition and physical activity counseling plus basic mental health screening and support. Senior Vice President Elin Jäger notes that the expansion forms part of Novo’s updated sustainability strategy launching the following week.
A company that sells weight loss drugs at massive scale simultaneously funds large-scale prevention work. The pairing creates a useful tension for readers who question pharma’s public health messaging: commercial success in treating obesity sits alongside measurable investment in stopping the condition before it starts.
Novo also sets its sights on the hair-loss market as it seeks growth areas beyond Ozempic and Wegovy. Chief Scientific Officer Martin Lange explains that some of the science now under pursuit for hair loss roots itself in endocrinology, the hormone-focused field where Novo holds long expertise.
“We could leverage our scientific knowledge potentially moving into that space,” Lange says. “It’s not necessarily what we’ll pursue first, but that would be a clear possibility.”
Hair loss sits on a broader list of potential adjacencies that includes addiction and menopause, areas where Novo sees overlap with either its core scientific strengths or the direct-to-consumer marketing skills it has built around weight-loss drugs.
Doustdar stresses that the company wants to pursue categories where its consumer-facing capabilities give it a chance “to win.” The firm also looks at new potential treatments for heart disease, liver and blood disorders and plans both bolt-on deals and faster advancement of its internal pipeline.
Also Read: GLP-1 Side Effects: Tips for Gastrointestinal Comfort 2026 Update
All three announcements land roughly a year into Mike Doustdar’s tenure as CEO. Together they mark Doustdar’s early style of strong focus on oral drugs, wider prevention work, and moves into new consumer markets.
Where earlier strategy centered on a single-bet injectable franchise, the current approach balances pills that already command dominant oral share, prevention work that reaches tens of millions of children, and exploratory moves into hair loss and related fields.
This combination positions Novo for multiple scenarios in a market that could reach USD 100–150 billion by 2030 while addressing both commercial and reputational pressures head-on.
.jpg)
